Actively Recruiting
Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
Led by Women's Hospital School Of Medicine Zhejiang University · Updated on 2025-12-18
59
Participants Needed
1
Research Sites
251 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Efficacy evaluation of camrelizumab combined with chemotherapy for adjuvant treatment of patients with pathologically confirmed lymph node-positive cervical cancer after staging surgery.
CONDITIONS
Official Title
Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with cervical cancer staged FIGO2018 IIIC1p or IIIC2p after radical surgery
- Positive PD-L1 expression
- ECOG score 1 or less
You will not qualify if you...
- Positive parametrium or surgical margin
- Incomplete radical surgery
- Residual target lesions
- Active autoimmune disease or autoimmune disease requiring systemic treatment
- Previous treatment with immune checkpoint inhibitors
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Women's Hospital, School of Medicine, Zhejiang University
Hangzhou, Zhejiang, China, 310000
Actively Recruiting
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here